Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation
Martin Böttcher(Otto-von-Guericke-Universität Magdeburg), Dimitrios Mougiakakos(Otto-von-Guericke-Universität Magdeburg), Regina Jitschin(Friedrich-Alexander-Universität Erlangen-Nürnberg), Martina Haibach(Friedrich-Alexander-Universität Erlangen-Nürnberg), Andreas D. Hofmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Heiko Bruns(Friedrich-Alexander-Universität Erlangen-Nürnberg), Romy Loschinski(Otto-von-Guericke-Universität Magdeburg), Andréas Mackensen(University Medical Center Freiburg), Katarina Le Blanc(Karolinska University Hospital), Domenica Saul(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 60
Related Papers
Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation
|Biology of Blood and Marrow Transplantation|2005|481
Do Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties?
|Stem Cells|2014|407
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?
|Stem Cells|2012|371